business

business

U.S. FDA approves Inluriyo (imlunestrant) for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer - Eli Lilly and Company

Breaking News: New Insights into AROMATASE INHIBITORS and HER2+ BREAST CANCER The treatment of breast cancer patients with estrogen receptor-positive (ER+) and human epidermal growth factor receptor 2-positive (HER2+) metastatic disease has recently seen a significant development. Inluriyo's lead compound, monotherapy, was found to have an unprecedented effect

By Lau Chi Fung